{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:14:58Z","timestamp":1794482098305,"version":"4.9.1"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["ERC-834682"],"award-info":[{"award-number":["ERC-834682"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/Y014847\/1"],"award-info":[{"award-number":["MR\/Y014847\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Methusalem grant KULeuven"},{"DOI":"10.13039\/100017885","name":"Queen Elisabeth Medical Foundation for Neurosciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017885","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Belgian Alzheimer Research Foundation"},{"name":"The Alzheimer\u2019s Association USA"},{"name":"Opening the Future"},{"name":"Bax-Van Luffelen foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal, i.e. slowing of Alzheimer\u2019s disease (AD) progression. However, antibody therapy may not be the optimal therapeutic modality for AD prevention, as we will discuss in the context of the earlier small molecules described as \u201c\u03b3-secretase modulators\u201d (GSM). We review here the structure, function, and pathobiology of \u03b3-secretases, with a focus on how mutations in presenilin genes result in early-onset AD. Significant progress has been made in generating compounds that act in a manner opposite to pathogenic presenilin mutations: they stabilize the proteinase-substrate complex, thereby increasing the processivity of substrate cleavage and altering the size spectrum of A\u03b2 peptides produced. We propose the term \u201c\u03b3-secretase allosteric stabilizers\u201d (GSAS) to distinguish these compounds from the rather heterogenous class of GSM. The GSAS represent, in theory, a precision medicine approach to the prevention of amyloid deposition, as they specifically target a discrete aspect in a complex cell biological signalling mechanism that initiates the pathological processes leading to Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.1038\/s44318-024-00057-w","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T09:06:05Z","timestamp":1708679165000},"page":"887-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of \u03b3-secretases"],"prefix":"10.1038","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-5819","authenticated-orcid":false,"given":"Bart","family":"De Strooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Karran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"57_CR1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/nn.2433","volume":"12","author":"E Abramov","year":"2009","unstructured":"Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I (2009) Amyloid-\u0392 as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12:1567\u20131576","journal-title":"Nat Neurosci"},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.15252\/emmm.201707561","volume":"9","author":"H Acx","year":"2017","unstructured":"Acx H, Serneels L, Radaelli E, Muyldermans S, Vincke C, Pepermans E, M\u00fcller U, Ch\u00e1vez\u2010Guti\u00e9rrez L, De Strooper B (2017) Inactivation of \u03b3\u2010secretases leads to accumulation of substrates and non\u2010Alzheimer neurodegeneration. EMBO Mol Med 9:1088\u20131099","journal-title":"EMBO Mol Med"},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cpt.1570","volume":"107","author":"JE Ahn","year":"2020","unstructured":"Ahn JE, Carrieri C, Dela Cruz F, Fullerton T, Hajos-Korcsok E, He P, Kantaridis C, Leurent C, Liu R, Mancuso J et al (2020) Pharmacokinetic and pharmacodynamic effects of a \u03b3-secretase modulator, PF-06648671, on CSF amyloid-\u03b2 peptides in randomized phase I studies. Clin Pharmacol Ther 107:211\u2013220","journal-title":"Clin Pharmacol Ther"},{"key":"57_CR4","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S (2023) Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis. Neurology 100:e2114\u2013e2124","journal-title":"Neurology"},{"key":"57_CR5","doi-asserted-by":"crossref","first-page":"e11182","DOI":"10.7554\/eLife.11182","volume":"4","author":"X Bai","year":"2015","unstructured":"Bai X, Rajendra E, Yang G, Shi Y, Scheres SHW (2015a) Sampling the conformational space of the catalytic subunit of human \u03b3-secretase. Elife 4:e11182","journal-title":"Elife"},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature14892","volume":"525","author":"XC Bai","year":"2015","unstructured":"Bai XC, Yan C, Yang G, Lu P, Ma D, Sun L, Zhou R, Scheres SHW, Shi Y (2015b) An atomic structure of human \u03b3-secretase. Nature 525:212\u2013217","journal-title":"Nature"},{"key":"57_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1365-4624.1997.00012.x","volume":"1","author":"R Baumeister","year":"1997","unstructured":"Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Gr\u00fcnberg J, Haass C (1997) Human presenilin-1, but not familial Alzheimer\u2019s disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct 1:149\u2013159","journal-title":"Genes Funct"},{"key":"57_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1474-4422(09)70332-1","volume":"9","author":"BA Bergmans","year":"2010","unstructured":"Bergmans BA, De Strooper B (2010) \u03b3-secretases: from cell biology to therapeutic strategies. Lancet Neurol 9:215\u2013226","journal-title":"Lancet Neurol"},{"key":"57_CR9","doi-asserted-by":"crossref","unstructured":"Best JD, Jay MT, Otu F, Churcher I, Reilly M, Morentin-Gutierrez P, Pattison C, Harrison T, Shearman MS, Atack JR (2006) In vivo characterization of A\u03b2(40) changes in brain and cerebrospinal fluid using the novel \u03b3-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1- trifluoromethanesulfonamide (MRK-560) in the rat. J Pharmacol Exp Ther 317:786\u2013790","DOI":"10.1124\/jpet.105.100271"},{"key":"57_CR10","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1021\/jacs.1c10533","volume":"144","author":"A Bhattarai","year":"2022","unstructured":"Bhattarai A, Devkota S, Do HN, Wang J, Bhattarai S, Wolfe MS, Miao Y (2022) Mechanism of tripeptide trimming of amyloid \u03b2-peptide 49 by \u03b3-secretase. J Am Chem Soc 144:6215\u20136226","journal-title":"J Am Chem Soc"},{"key":"57_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jalz.2015.08.166","volume":"12","author":"M Bilgel","year":"2016","unstructured":"Bilgel M, An Y, Zhou Y, Wong DF, Prince JL, Ferrucci L, Resnick SM (2016) Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimers Dement 12:373\u2013379","journal-title":"Alzheimers Dement"},{"key":"57_CR12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/mp.2015.74","volume":"20","author":"M Brendel","year":"2015","unstructured":"Brendel M, Jaworska A, Herms J, Trambauer J, R\u00f6tzer C, Gildehaus F-J, Carlsen J, Cumming P, Bylund J, Luebbers T et al (2015) Amyloid-PET predicts inhibition of de novo plaque formation upon chronic \u03b3-secretase modulator treatment. Mol Psychiatry 20:1179\u20131187","journal-title":"Mol Psychiatry"},{"key":"57_CR14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0092-8674(00)80675-3","volume":"100","author":"MS Brown","year":"2000","unstructured":"Brown MS, Ye J, Rawson RB, Goldstein JL (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391\u2013398","journal-title":"Cell"},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"fcaa041","DOI":"10.1093\/braincomms\/fcaa041","volume":"2","author":"SC Burnham","year":"2020","unstructured":"Burnham SC, Fandos N, Fowler C, P\u00e9rez-Grijalba V, Dore V, Doecke JD, Shishegar R, Cox T, Fripp J, Rowe C et al (2020) Longitudinal evaluation of the natural history of amyloid-\u03b2 in plasma and brain. Brain Commun 2:fcaa041","journal-title":"Brain Commun"},{"key":"57_CR16","doi-asserted-by":"crossref","first-page":"14426","DOI":"10.1021\/acs.jmedchem.1c00904","volume":"64","author":"MG Bursavich","year":"2021","unstructured":"Bursavich MG, Harrison BA, Acharya R, Costa DE, Freeman EA, Hrdlicka LA, Jin H, Kapadnis S, Moffit JS, Murphy D et al (2021) Discovery of the oxadiazine FRM-024: a potent CNS-penetrant gamma secretase modulator. J Med Chem 64:14426\u201314447","journal-title":"J Med Chem"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"12272","DOI":"10.1523\/JNEUROSCI.1628-17.2017","volume":"37","author":"T Cai","year":"2017","unstructured":"Cai T, Yonaga M, Tomita T (2017) Activation of \u03b3-secretase trimming activity by topological changes of transmembrane domain 1 of presenilin 1. J Neurosci 37:12272\u201312280","journal-title":"J Neurosci"},{"key":"57_CR18","doi-asserted-by":"crossref","unstructured":"Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F et al (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65:664\u2013670","DOI":"10.1086\/302553"},{"key":"57_CR19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam M-M, Jamshidi P (2023) Neuropathology of anti-amyloid-\u03b2 immunotherapy: a case report. J Alzheimers Dis 93:803\u2013813","journal-title":"J Alzheimers Dis"},{"key":"57_CR20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Ch\u00e1vez-Guti\u00e9rrez","year":"2012","unstructured":"Ch\u00e1vez-Guti\u00e9rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H et al (2012) The mechanism of \u03b3-Secretase dysfunction in familial Alzheimer disease. EMBO J 31:2261\u20132274","journal-title":"EMBO J"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s42003-023-05039-y","volume":"6","author":"S-Y Chen","year":"2023","unstructured":"Chen S-Y, Feilen LP, Ch\u00e1vez-Guti\u00e9rrez L, Steiner H, Zacharias M (2023) Enzyme-substrate hybrid \u03b2-sheet controls geometry and water access to the \u03b3-secretase active site. Commun Biol 6:670","journal-title":"Commun Biol"},{"key":"57_CR22","doi-asserted-by":"crossref","first-page":"668207","DOI":"10.3389\/fimmu.2021.668207","volume":"12","author":"PF Christopoulos","year":"2021","unstructured":"Christopoulos PF, Gj\u00f8lberg TT, Kr\u00fcger S, Haraldsen G, Andersen JT, Sundlis\u00e6ter E (2021) Targeting the Notch signaling pathway in chronic inflammatory diseases. Front Immunol 12:668207","journal-title":"Front Immunol"},{"key":"57_CR23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bmcl.2005.10.009","volume":"16","author":"I Churcher","year":"2006","unstructured":"Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S et al (2006) 4-Substituted cyclohexyl sulfones as potent, orally active \u03b3-secretase inhibitors. Bioorg Med Chem Lett 16:280\u2013284","journal-title":"Bioorg Med Chem Lett"},{"key":"57_CR24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, Van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T et al (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72:1324\u20131333","journal-title":"JAMA Neurol"},{"key":"57_CR117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","volume":"38","author":"B De Strooper","year":"2003","unstructured":"De Strooper B (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38:9\u201312","journal-title":"Neuron"},{"key":"57_CR118","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.embor.7400897","volume":"8","author":"B De Strooper","year":"2007","unstructured":"De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8:141\u2013146","journal-title":"EMBO Rep"},{"key":"57_CR119","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","volume":"159","author":"B De Strooper","year":"2014","unstructured":"De Strooper B (2014) Lessons from a failed \u03b3-secretase Alzheimer trial. Cell 159:721\u2013726","journal-title":"Cell"},{"key":"57_CR120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Rayk WJ et al (1999) A presenilin-1-dependent g-secretase-like protease mediates release of Notch intracellular domain. Nature 398:518\u2013522","journal-title":"Nature"},{"key":"57_CR121","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E (2016) The cellular phase of Alzheimer\u2019s disease. Cell 164:603\u2013615. https:\/\/doi.org\/10.1016\/j.cell.2015.12.056","journal-title":"Cell"},{"key":"57_CR122","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/34910","volume":"391","author":"B De Strooper","year":"1998","unstructured":"De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387\u2013390","journal-title":"Nature"},{"key":"57_CR25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nn.3376","volume":"16","author":"I Dolev","year":"2013","unstructured":"Dolev I, Fogel H, Milshtein H, Berdichevsky Y, Lipstein N, Brose N, Gazit N, Slutsky I (2013) Spike bursts increase amyloid-\u03b2 40\/42 ratio by inducing a presenilin-1 conformational change. Nat Neurosci 16:587\u2013595","journal-title":"Nat Neurosci"},{"key":"57_CR26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","journal-title":"N Engl J Med"},{"key":"57_CR27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/383710a0","volume":"383","author":"K Duff","year":"1996","unstructured":"Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D et al (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710\u2013713","journal-title":"Nature"},{"key":"57_CR29","doi-asserted-by":"crossref","first-page":"37181","DOI":"10.1074\/jbc.C111.276972","volume":"286","author":"A Ebke","year":"2011","unstructured":"Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, Steiner H (2011) Novel \u03b3-secretase enzyme modulators directly target presenilin protein. J Biol Chem 286:37181\u201337186","journal-title":"J Biol Chem"},{"key":"57_CR30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncb960","volume":"5","author":"D Edbauer","year":"2003","unstructured":"Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C (2003) Reconstitution of gamma-secretase activity. Nat Cell Biol 5:486\u2013488","journal-title":"Nat Cell Biol"},{"key":"57_CR31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M et al (2019) Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Eng J Med 380:1408\u20131420","journal-title":"N Eng J Med"},{"key":"57_CR32","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","volume":"96","author":"ME Farrell","year":"2021","unstructured":"Farrell ME, Jiang S, Schultz AP, Properzi MJ, Price JC, Becker JA, Jacobs HIL, Hanseeuw BJ, Rentz DM, Villemagne VL et al (2021) Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology 96:e619\u2013e631","journal-title":"Neurology"},{"key":"57_CR33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.celrep.2014.04.024","volume":"7","author":"H Fogel","year":"2014","unstructured":"Fogel H, Frere S, Segev O, Bharill S, Shapira I, Gazit N, O\u2019Malley T, Slomowitz E, Berdichevsky Y, Walsh DM et al (2014) APP homodimers transduce an amyloid-\u03b2-mediated increase in release probability at excitatory synapses. Cell Rep 7:1560\u20131576","journal-title":"Cell Rep"},{"key":"57_CR34","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1021\/bi049399k","volume":"43","author":"S Funamoto","year":"2004","unstructured":"Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y (2004) Truncated carboxyl-terminal fragments of \u03b2-amyloid precursor protein are processed to amyloid \u03b2-proteins 40 and 42. Biochemistry 43:13532\u201313540","journal-title":"Biochemistry"},{"key":"57_CR35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaad.2017.02.055","volume":"77","author":"A Garg","year":"2017","unstructured":"Garg A, Strunk A (2017) Risk of Alzheimer\u2019s disease is not increased among patients with hidradenitis suppurativa: a retrospective population-based cohort analysis. J Am Acad Dermatol 77:176\u2013177","journal-title":"J Am Acad Dermatol"},{"key":"57_CR36","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","volume":"1828","author":"TE Golde","year":"2013","unstructured":"Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) \u03b3-Secretase inhibitors and modulators. Biochim Biophys Acta 1828:2898\u20132907","journal-title":"Biochim Biophys Acta"},{"key":"57_CR37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Brown MS (2015) A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161:161\u2013172.","journal-title":"Cell"},{"key":"57_CR38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S et al (2023) Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors. N Engl J Med 388:898\u2013912","journal-title":"N Engl J Med"},{"key":"57_CR39","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557\u20132564","journal-title":"JAMA"},{"key":"57_CR40","volume":"13","author":"X Guo","year":"2022","unstructured":"Guo X, Wang Y, Zhou J, Jin C, Wang J, Jia B, Jing D, Yan C, Lei J, Zhou R et al (2022) Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560. Nat Commun 13:6299","journal-title":"Nat Commun"},{"key":"57_CR41","doi-asserted-by":"crossref","first-page":"eaau6246","DOI":"10.1126\/scitranslmed.aau6246","volume":"11","author":"RA Habets","year":"2019","unstructured":"Habets RA, De Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, Narlawar R, Demeyer S, Dooley J, Liston A et al (2019) Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med 11:eaau6246","journal-title":"Sci Transl Med"},{"key":"57_CR42","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1016\/j.molcel.2023.10.029","volume":"83","author":"P Hou","year":"2023","unstructured":"Hou P, Zielonka M, Serneels L, Martinez-Muriana A, Fattorelli N, Wolfs L, Poovathingal S, T\u2019Syen D, Balusu S, Theys T et al (2023) The \u03b3-secretase substrate proteome and its role in cell signaling regulation. Mol Cell 83:4106\u20134122.e10","journal-title":"Mol Cell"},{"key":"57_CR43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41586-020-2681-2","volume":"586","author":"JY Hur","year":"2020","unstructured":"Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, Barros M, Li T, Nie P, Zhai Y et al (2020) The innate immunity protein IFITM3 modulates \u03b3-secretase in Alzheimer\u2019s disease. Nature 586:735\u2013740","journal-title":"Nature"},{"key":"57_CR44","doi-asserted-by":"crossref","first-page":"eadg1925","DOI":"10.1126\/sciadv.adg1925","volume":"9","author":"E Im","year":"2023","unstructured":"Im E, Jiang Y, Stavrides PH, Darji S, Erdjument-Bromage H, Neubert TA, Choi JY, Wegiel J, Lee J-H, Nixon RA (2023) Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr682-phosphorylated APP \u03b2CTF. Sci Adv 9:eadg1925","journal-title":"Sci Adv"},{"key":"57_CR45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1476-5381.2008.00097.x","volume":"156","author":"BP Imbimbo","year":"2009","unstructured":"Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer\u2019s disease. Br J Pharmacol 156:982\u2013993","journal-title":"Br J Pharmacol"},{"key":"57_CR46","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O et al (2019) Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93:e322\u2013e333","journal-title":"Neurology"},{"key":"57_CR47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/molecules27010176","volume":"27","author":"A Ioppolo","year":"2021","unstructured":"Ioppolo A, Eccles M, Groth D, Verdile G, Agostino M (2021) Evaluation of virtual screening strategies for the identification of \u03b3-secretase inhibitors and modulators. Molecules 27:176","journal-title":"Molecules"},{"key":"57_CR48","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack","year":"2023","unstructured":"Jack CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, Schwarz CG, Lowe VJ, Ramanan VK, Vemuri P, Mielke MM, Knopman DS et al (2023) Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain 146:2029\u20132044","journal-title":"Brain"},{"key":"57_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, Vemuri P, Mielke MM, Roberts RO, Machulda MM et al (2017a) Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol 16:435\u2013444","journal-title":"Lancet Neurol"},{"key":"57_CR50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K et al (2017b) Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement 13:205\u2013216","journal-title":"Alzheimers Dement"},{"key":"57_CR51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Altomare D et al (2022) Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol 79:228\u2013243","journal-title":"JAMA Neurol"},{"key":"57_CR53","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.bbamem.2013.04.016","volume":"1828","author":"N Jurisch-Yaksi","year":"2013","unstructured":"Jurisch-Yaksi N, Sannerud R, Annaert W (2013) A fast growing spectrum of biological functions of \u03b3-secretase in development and disease. Biochim Biophys Acta 1828:2815\u20132827","journal-title":"Biochim Biophys Acta"},{"key":"57_CR54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 76:185\u2013205","journal-title":"Ann Neurol"},{"key":"57_CR55","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, Strooper B, De (2011) The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698\u2013712","journal-title":"Nat Rev Drug Discov"},{"key":"57_CR56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21:306\u2013318","journal-title":"Nat Rev Drug Discov"},{"issue":"1-15","key":"57_CR57","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11(1-15):e1\u2013e4","journal-title":"Alzheimers Dement"},{"key":"57_CR58","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.neuron.2010.08.018","volume":"67","author":"MZ Kounnas","year":"2010","unstructured":"Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L et al (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer\u2019s disease. Neuron 67:769\u2013780","journal-title":"Neuron"},{"key":"57_CR59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.trci.2019.06.006","volume":"5","author":"MZ Kounnas","year":"2019","unstructured":"Kounnas MZ, Durakoglugil MS, Herz J, Comer WT (2019) NGP 555, a \u03b3-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses. Alzheimer\u2019s Dement 5:458\u2013467","journal-title":"Alzheimer\u2019s Dement"},{"key":"57_CR60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.trci.2016.09.003","volume":"3","author":"MZ Kounnas","year":"2017","unstructured":"Kounnas MZ, Lane-Donovan C, Nowakowski DW, Herz J, Comer WT (2017) NGP 555, a \u03b3-secretase modulator, lowers the amyloid biomarker, A\u03b242 in cerebrospinal fluid while preventing Alzheimer\u2019s disease cognitive decline in rodents. Alzheimer\u2019s Dement 3:65\u201373","journal-title":"Alzheimer\u2019s Dement"},{"key":"57_CR61","doi-asserted-by":"crossref","first-page":"15240","DOI":"10.1074\/jbc.M110.213587","volume":"286","author":"B Kretner","year":"2011","unstructured":"Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G, Baumann K, Haass C, Steiner H (2011) Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem 286:15240\u201315251","journal-title":"J Biol Chem"},{"key":"57_CR62","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15252\/emmm.201505952","volume":"8","author":"B Kretner","year":"2016","unstructured":"Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn P, Kremmer E, Giese A, Lichtenthaler SF, Haass C, Arzberger T et al (2016) Generation and deposition of A\u03b243 by the virtually inactive presenilin\u20101 L435F mutant contradicts the presenilin loss\u2010of\u2010function hypothesis of Alzheimer\u2019s disease. EMBO Mol Med 8:458\u2013465","journal-title":"EMBO Mol Med"},{"key":"57_CR63","first-page":"e12326","volume":"14","author":"N Krishnadas","year":"2022","unstructured":"Krishnadas N, Dor\u00e9 V, Laws SM, Porter T, Lamb F, Bozinovski S, Villemagne VL, Rowe CC (2022) Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. Alzheimers Dement 14:e12326","journal-title":"Alzheimers Dement"},{"key":"57_CR64","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nm1235","volume":"11","author":"T Kukar","year":"2005","unstructured":"Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J et al (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11:545\u2013550","journal-title":"Nat Med"},{"key":"57_CR65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature07055","volume":"453","author":"TL Kukar","year":"2008","unstructured":"Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW et al (2008) Substrate-targeting gamma-secretase modulators. Nature 453:925\u2013929","journal-title":"Nature"},{"key":"57_CR52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Dor\u00e9 V, Grinberg LT, Huang E, Hwang J-H et al (2019) Multisite study of the relationships between antemortem [11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement 15:205\u2013216","journal-title":"Alzheimers Dement"},{"key":"57_CR66","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","volume":"41","author":"SM Landau","year":"2014","unstructured":"Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, Pontecorvo M, Baker SL, Jagust WJ, Alzheimer\u2019s Disease Neuroimaging Initiative (2014) Amyloid PET imaging in Alzheimer\u2019s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41:1398\u20131407","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"57_CR159","doi-asserted-by":"crossref","unstructured":"LaPoint MR, Baker SL, Landau SM, Harrison, TM, Jagust WJ (2022) Rates of \u03b2-amyloid deposition indicate widespread simultaneous accumulation throughout the brain. Neurobiol Aging 115:1\u201311","DOI":"10.1016\/j.neurobiolaging.2022.03.005"},{"key":"57_CR67","doi-asserted-by":"crossref","first-page":"e0144758","DOI":"10.1371\/journal.pone.0144758","volume":"10","author":"CB Lessard","year":"2015","unstructured":"Lessard CB, Cottrell BA, Maruyama H, Suresh S, Golde TE, Koo EH (2015) \u03b3-secretase modulators and APH1 isoforms modulate \u03b3-secretase cleavage but not position of \u03b5-cleavage of the amyloid precursor protein (APP). PLoS ONE 10:e0144758","journal-title":"PLoS ONE"},{"key":"57_CR69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13195-020-00622-5","volume":"12","author":"CB Lessard","year":"2020","unstructured":"Lessard CB, Rodriguez E, Ladd TB, Minter LM, Osborne BA, Miele L, Golde TE, Ran Y (2020) \u03b3-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse \u03b3-secretase modulators do not. Alzheimers Res Ther 12:61","journal-title":"Alzheimers Res Ther"},{"key":"57_CR70","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/377351a0","volume":"377","author":"D Levitan","year":"1995","unstructured":"Levitan D, Greenwald I (1995) Facilitation of lin-12-mediated signaling by sel-12, a Caenorhabditis elegans S182 Alzheimer\u2019s disease gene. Nature 377:351\u2013354","journal-title":"Nature"},{"key":"57_CR71","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/35015085","volume":"405","author":"YM Li","year":"2000","unstructured":"Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG et al (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689\u2013694","journal-title":"Nature"},{"key":"57_CR73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nature13567","volume":"512","author":"P Lu","year":"2014","unstructured":"Lu P, Bai XC, Ma D, Xie T, Yan C, Sun L, Yang G, Zhao Y, Zhou R, Scheres SHW et al (2014) Three-dimensional structure of human \u03b3-secretase. Nature 512:166\u2013170","journal-title":"Nature"},{"key":"57_CR74","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13578-021-00738-7","volume":"12","author":"JE Luo","year":"2022","unstructured":"Luo JE, Li Y-M (2022) Turning the tide on Alzheimer\u2019s disease: modulation of \u03b3-secretase. Cell Biosci 12:2","journal-title":"Cell Biosci"},{"key":"57_CR75","unstructured":"Martin Prince A, Wimo A, Guerchet M, Gemma-Claire Ali M, Wu Y-T, Prina M, Yee Chan K, Xia Z, World Alzheimer Report (2015) The Global Impact of Dementia An AnalysIs of Prevalence, Incidence, Cost and Trends. Alzheimer\u2019s Disease International (ADI), London"},{"key":"57_CR76","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1002\/onco.13627","volume":"26","author":"TR McCaw","year":"2021","unstructured":"McCaw TR, Inga E, Chen H, Jaskula-Sztul R, Dudeja V, Bibb JA, Ren B, Rose JB (2021) Gamma secretase inhibitors in cancer: a current perspective on clinical performance. Oncologist 26:e608\u2013e621","journal-title":"Oncologist"},{"key":"57_CR77","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1039\/D0MD00196A","volume":"11","author":"S Mekala","year":"2020","unstructured":"Mekala S, Nelson G, Li Y-M (2020) Recent developments of small molecule \u03b3-secretase modulators for Alzheimer\u2019s disease. RSC Med Chem 11:1003\u20131022","journal-title":"RSC Med Chem"},{"key":"57_CR78","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E et al (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med 28:1797\u20131801","journal-title":"Nat Med"},{"key":"57_CR79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2015.12.016","volume":"1633","author":"K Murakami","year":"2016","unstructured":"Murakami K, Watanabe T, Koike T, Kamata M, Igari T, Kondo S (2016) Pharmacological properties of a novel and potent \u03b3-secretase modulator as a therapeutic option for the treatment of Alzheimer\u2019s disease. Brain Res 1633:73\u201386","journal-title":"Brain Res"},{"key":"57_CR80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kft224","volume":"137","author":"K Nakano-Ito","year":"2014","unstructured":"Nakano-Ito K, Fujikawa Y, Hihara T, Shinjo H, Kotani S, Suganuma A, Aoki T, Tsukidate K (2014) E2012-induced cataract and its predictive biomarkers. Toxicol Sci 137:249\u2013258","journal-title":"Toxicol Sci"},{"key":"57_CR81","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jid.2017.09.051","volume":"138","author":"G O\u2019Sullivan Coyne","year":"2018","unstructured":"O\u2019Sullivan Coyne G, Woodring TS, Lee CCR, Chen AP, Kong HH (2018) Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase. J Invest Dermatol 138:979\u2013981","journal-title":"J Invest Dermatol"},{"key":"57_CR82","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ejhf.1360","volume":"20","author":"M Packer","year":"2018","unstructured":"Packer M, Pitt B (2018) Future large-scale clinical trials in cardiovascular medicine: challenges and uncertainties. Eur J Heart Fail 20:1645\u20131648","journal-title":"Eur J Heart Fail"},{"key":"57_CR83","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1074\/jbc.M708754200","volume":"283","author":"RM Page","year":"2008","unstructured":"Page RM, Baumann K, Tomioka M, P\u00e9rez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H et al (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283:677\u2013683","journal-title":"J Biol Chem"},{"key":"57_CR84","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1038\/s41380-022-01518-6","volume":"27","author":"D Petit","year":"2022","unstructured":"Petit D, Fern\u00e1ndez SG, Zoltowska KM, Enzlein T, Ryan NS, O\u2019Connor A, Szaruga M, Hill E, Vandenberghe R, Fox NC et al (2022a) A\u03b2 profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry 27:2821\u20132832","journal-title":"Mol Psychiatry"},{"key":"57_CR85","doi-asserted-by":"crossref","first-page":"e111084","DOI":"10.15252\/embj.2022111084","volume":"41","author":"D Petit","year":"2022","unstructured":"Petit D, Hitzenberger M, Koch M, Lismont S, Zoltowska KM, Enzlein T, Hopf C, Zacharias M, Ch\u00e1vez\u2010Guti\u00e9rrez L (2022b) Enzyme\u2013substrate interface targeting by imidazole\u2010based \u03b3\u2010secretase modulators activates \u03b3\u2010secretase and stabilizes its interaction with APP. EMBO J 41:e111084","journal-title":"EMBO J"},{"key":"57_CR86","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem 25:1605\u20131612","journal-title":"J Comput Chem"},{"key":"57_CR87","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1021\/bi2007146","volume":"50","author":"O Quintero-Monzon","year":"2011","unstructured":"Quintero-Monzon O, Martin MM, Fernandez MA, Cappello CA, Krzysiak AJ, Osenkowski P, Wolfe MS (2011) Dissociation between the processivity and total activity of \u03b3-secretase: implications for the mechanism of Alzheimer\u2019s disease-causing presenilin mutations. Biochemistry 50:9023\u20139035","journal-title":"Biochemistry"},{"key":"57_CR88","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ et al (2023) The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement 19:1227\u20131233","journal-title":"Alzheimers Dement"},{"key":"57_CR89","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc3035","volume":"11","author":"P Ranganathan","year":"2011","unstructured":"Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11:338\u2013351","journal-title":"Nat Rev Cancer"},{"key":"57_CR90","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/acsmedchemlett.0c00109","volume":"11","author":"H Ratni","year":"2020","unstructured":"Ratni H, Alker A, Bartels B, Bissantz C, Chen W, Gerlach I, Limberg A, Lu M, Neidhart W, Pichereau S et al (2020) Discovery of RO7185876, a highly potent \u03b3-secretase modulator (GSM) as a potential treatment for Alzheimer\u2019s disease. ACS Med Chem Lett 11:1257\u20131268","journal-title":"ACS Med Chem Lett"},{"key":"57_CR91","doi-asserted-by":"crossref","unstructured":"Rogaev EI, Sherrington R (1995) Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 376:775\u2013778","DOI":"10.1038\/376775a0"},{"key":"57_CR92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1326-7-61","volume":"7","author":"K Rogers","year":"2012","unstructured":"Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller M-J, Spaulding D, Yang Z et al (2012) Modulation of \u03b3-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener 7:61","journal-title":"Mol Neurodegener"},{"key":"57_CR93","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","volume":"57","author":"CC Rowe","year":"2016","unstructured":"Rowe CC, Jones G, Dor\u00e9 V, Pejoska S, Margison L, Mulligan RS, Chan JG, Young K, Villemagne VL (2016) Standardized expression of 18F-NAV4694 and 11C-PiB \u03b2-amyloid PET results with the centiloid scale. J Nucl Med 57:1233\u20131237","journal-title":"J Nucl Med"},{"key":"57_CR94","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, Adamson G, Kenny J, Beck J, Chavez-Gutierrez L et al (2016) Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol 15:1326\u20131335","journal-title":"Lancet Neurol"},{"key":"57_CR95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JBS et al (2014) Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83:253\u2013260","journal-title":"Neurology"},{"key":"57_CR96","doi-asserted-by":"crossref","first-page":"e20202560","DOI":"10.1084\/jem.20202560","volume":"218","author":"KD Rynearson","year":"2021","unstructured":"Rynearson KD, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P, Hug B, Sawa M, Becker A, Spencer B et al (2021) Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J Exp Med 218:e20202560","journal-title":"J Exp Med"},{"key":"57_CR97","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nn.2858","volume":"14","author":"T Saito","year":"2011","unstructured":"Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J et al (2011) Potent amyloidogenicity and pathogenicity of A\u03b2 243. Nat Neurosci 14:1023\u20131032","journal-title":"Nat Neurosci"},{"key":"57_CR98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Eng J Med 370:322\u2013333","journal-title":"N Eng J Med"},{"key":"57_CR99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, Pavia J, Ni\u00f1erola-Baiz\u00e1n A, Perissinotti A, Lome\u00f1a F et al (2019) Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther 11:27","journal-title":"Alzheimers Res Ther"},{"key":"57_CR100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","volume":"166","author":"R Sannerud","year":"2016","unstructured":"Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, De Baets G, De Wever V, Habets R, Baert V et al (2016) Restricted location of PSEN2\/\u03b3-secretase determines substrate specificity and generates an intracellular A\u03b2 pool. Cell 166:193\u2013208","journal-title":"Cell"},{"key":"57_CR101","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1021\/acschemneuro.1c00313","volume":"12","author":"\u00c1 Santiago","year":"2021","unstructured":"Santiago \u00c1, Guzm\u00e1n-Ocampo DC, Aguayo-Ortiz R, Dominguez L (2021) Characterizing the chemical space of \u03b3-secretase inhibitors and modulators. ACS Chem Neurosci 12:2765\u20132775","journal-title":"ACS Chem Neurosci"},{"key":"57_CR102","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/molecules26102843","volume":"26","author":"S Saretz","year":"2021","unstructured":"Saretz S, Basset G, Useini L, Laube M, Pietzsch J, Dra\u010da D, Maksimovi\u0107-Ivani\u0107 D, Trambauer J, Steiner H, Hey-Hawkins E (2021) Modulation of \u03b3-secretase activity by a carborane-based flurbiprofen analogue. Molecules 26:2843","journal-title":"Molecules"},{"key":"57_CR103","doi-asserted-by":"crossref","first-page":"24294","DOI":"10.1074\/jbc.M211161200","volume":"278","author":"T Sato","year":"2003","unstructured":"Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K et al (2003) Potential link between amyloid \u03b2-protein 42 and C-terminal fragment \u03b3 49-99 of \u03b2-amyloid precursor protein. J Biol Chem 278:24294\u201320301","journal-title":"J Biol Chem"},{"key":"57_CR104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2015.12.006","volume":"103","author":"RH Scannevin","year":"2016","unstructured":"Scannevin RH, Chollate S, Brennan MS, Snodgrass-Belt PA, Peng H, Xu L, Jung M-Y, Bussiere T, Arastu MF, Talreja T et al (2016) BIIB042, a novel \u03b3-secretase modulator, reduces amyloidogenic A\u03b2 isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer\u2019s disease. Neuropharmacology 103:57\u201368","journal-title":"Neuropharmacology"},{"key":"57_CR105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2:864\u2013870","journal-title":"Nat Med"},{"key":"57_CR106","doi-asserted-by":"publisher","unstructured":"Schultz S, Liu L, Schultz AP, Fitzpatrick CD, Levin R (2023) Functional variations in gamma-secretase activity are critical determinants of the clinical, biomarker, and cognitive progression of autosomal domainant Alzheimer\u2019s disease. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.07.04.547688","DOI":"10.1101\/2023.07.04.547688"},{"key":"57_CR107","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"57_CR108","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.1171176","volume":"324","author":"L Serneels","year":"2009","unstructured":"Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horr\u00e9 K, Houtvin TVan, Esselmann H, Paul S, Sch\u00e4fer MK, Berezovska O et al (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer\u2019s disease. Science 324:639\u2013642","journal-title":"Science"},{"key":"57_CR109","doi-asserted-by":"crossref","first-page":"104794","DOI":"10.1016\/j.jbc.2023.104794","volume":"299","author":"L Serneels","year":"2023","unstructured":"Serneels L, Narlawar R, Perez-Benito L, Municoy M, Guallar V, T\u2019Syen D, Dewilde M, Bischoff F, Fraiponts E, Tresadern G et al (2023) Selective inhibitors of the PSEN1-gamma-secretase complex. J Biol Chem 299:104794","journal-title":"J Biol Chem"},{"key":"57_CR110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1073\/pnas.0608332104","volume":"104","author":"J Shen","year":"2007","unstructured":"Shen J, Kelleher RJ (2007) The presenilin hypothesis of Alzheimer\u2019s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104:403\u2013409","journal-title":"Proc Natl Acad Sci USA"},{"key":"57_CR111","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/hmg\/5.7.985","volume":"5","author":"R Sherrington","year":"1996","unstructured":"Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, Levesque G, Rogaev EI, Lin C, Liang Y et al (1996) Alzheimer\u2019s disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5:985\u2013988","journal-title":"Hum Mol Genet"},{"key":"57_CR112","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375:754\u2013760","journal-title":"Nature"},{"key":"57_CR160","doi-asserted-by":"crossref","unstructured":"Shi TW, Cao W, Zhao QZ, Yu HX, Zhang SS, Hao YB (2023) Effects of NCSTN Mutation on Hair Follicle Components in Mice. Dermatology 239:60\u201371","DOI":"10.1159\/000525526"},{"key":"57_CR113","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527","journal-title":"JAMA"},{"key":"57_CR114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.116.232256","volume":"358","author":"HD Soares","year":"2016","unstructured":"Soares HD, Gasior M, Toyn JH, Wang JS, Hong Q, Berisha F, Furlong MT, Raybon J, Lentz KA, Sweeney F et al (2016) The \u03b3-secretase modulator, BMS-932481, modulates A\u03b2 peptides in the plasma and cerebrospinal fluid of healthy volunteerss. J Pharmacol Exp Ther 358:138\u2013150","journal-title":"J Pharmacol Exp Ther"},{"key":"57_CR115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, Maldonado J, Donahue MJ, Schultz D, Coyne TM et al (2023) Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun 14:8220","journal-title":"Nat Commun"},{"key":"57_CR116","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R et al (2023) Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med 389:1096\u20131110","journal-title":"N Engl J Med"},{"key":"57_CR123","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/19091","volume":"398","author":"G Struhl","year":"1999","unstructured":"Struhl G, Greenwald I (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398:522\u2013525","journal-title":"Nature"},{"key":"57_CR124","first-page":"E476","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun L, Zhou R, Yang G, Shi Y (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proc Natl Acad Sci USA 114:E476\u2013E485","journal-title":"Proc Natl Acad Sci USA"},{"key":"57_CR125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cell.2017.07.004","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, Munteanu B, Lismont S, Veugelen S, Horr\u00e9 K, Mercken M, Saido TC, Ryan NS, De Vos T, Savvides SN et al (2017) Alzheimer\u2019s-causing mutations shift A\u03b2 length by destabilizing \u03b3-secretase-A\u03b2n interactions. Cell 170:443\u2013456.e14","journal-title":"Cell"},{"key":"57_CR126","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1084\/jem.20150892","volume":"212","author":"M Szaruga","year":"2015","unstructured":"Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, Ryan NS, Lashley T, Fox NC, Murayama S et al (2015) Qualitative changes in human \u03b3-secretase underlie familial Alzheimer\u2019s disease. J Exp Med 212:2003\u20132013","journal-title":"J Exp Med"},{"key":"57_CR127","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1523\/JNEUROSCI.1320-09.2009","volume":"29","author":"K Tabuchi","year":"2009","unstructured":"Tabuchi K, Chen G, S\u00fcdhof TC, Shen J (2009) Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. J Neurosci 29:7290\u20137301","journal-title":"J Neurosci"},{"key":"57_CR129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature01506","volume":"422","author":"N Takasugi","year":"2003","unstructured":"Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422:438\u2013441","journal-title":"Nature"},{"key":"57_CR128","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) \u03b3-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of \u03b2-carboxyl terminal fragment. J Neurosci 29:13042\u201313052","journal-title":"J Neurosci"},{"key":"57_CR130","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1073\/pnas.1402171111","volume":"111","author":"K Takeo","year":"2014","unstructured":"Takeo K, Tanimura S, Shinoda T, Osawa S, Zahariev IK, Takegami N, Ishizuka-Katsura Y, Shinya N, Takagi-Niidome S, Tominaga A et al (2014) Allosteric regulation of \u03b3-secretase activity by a phenylimidazole-type \u03b3-secretase modulator. Proc Natl Acad Sci USA 111:10544\u201310549","journal-title":"Proc Natl Acad Sci USA"},{"key":"57_CR131","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3233\/JAD-180829","volume":"66","author":"N Tang","year":"2018","unstructured":"Tang N, Kepp KP (2018) A\u03b242\/A\u03b240 ratios of presenilin 1 mutations correlate with clinical onset of Alzheimer\u2019s disease. J Alzheimers Dis 66:939\u2013945","journal-title":"J Alzheimers Dis"},{"key":"57_CR132","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nm.3023","volume":"19","author":"A Thathiah","year":"2013","unstructured":"Thathiah A, Horr\u00e9 K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, De Kloe G, Munck S, De Strooper B (2013) \u03b2-Arrestin 2 regulates A\u03b2 generation and \u03b3-secretase activity in Alzheimer\u2019s disease. Nat Med 19:44\u201349","journal-title":"Nat Med"},{"key":"57_CR133","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.15064","volume":"177","author":"P Theut Riis","year":"2017","unstructured":"Theut Riis P, Egeberg A, Gislason GH, Jemec GB (2017) Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease. Br J Dermatol 177:273\u2013275","journal-title":"Br J Dermatol"},{"key":"57_CR134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80291-3","volume":"17","author":"G Thinakaran","year":"1996","unstructured":"Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M et al (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181\u2013190","journal-title":"Neuron"},{"key":"57_CR135","doi-asserted-by":"crossref","first-page":"33273","DOI":"10.1074\/jbc.M011152200","volume":"276","author":"T Tomita","year":"2001","unstructured":"Tomita T, Watabiki T, Takikawa R, Morohashi Y, Takasugi N, Kopan R, De Strooper B, Iwatsubo T (2001) The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins. J Biol Chem 276:33273\u201333281","journal-title":"J Biol Chem"},{"key":"57_CR136","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-15-66","volume":"15","author":"Y Tona","year":"2014","unstructured":"Tona Y, Hamaguchi K, Ishikawa M, Miyoshi T, Yamamoto N, Yamahara K, Ito J, Nakagawa T (2014) Therapeutic potential of a gamma-secretase inhibitor for hearing restoration in a guinea pig model with noise-induced hearing loss. BMC Neurosci 15:66","journal-title":"BMC Neurosci"},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1476-5381.2011.01207.x","volume":"163","author":"B Van Broeck","year":"2011","unstructured":"Van Broeck B, Chen J-M, Tr\u00e9ton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, Rowley A (2011) Chronic treatment with a novel \u03b3-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer\u2019s disease. Br J Pharmacol 163:375\u2013389","journal-title":"Br J Pharmacol"},{"key":"57_CR161","doi-asserted-by":"crossref","unstructured":"van der Kall LM, Truong T, Burnham SC, Dor\u00e9 V, Mulligan RS, Bozinovski S, Lamb F, Bourgeat P, Fripp J, Schultz S, Lim YY, Laws SM, Ames D, Fowler C, Rainey-Smith SR, Martins RN, Salvado O, Robertson J, Maruff P, Masters CL, Villemagne VL, Rowe CC (2021) Association of \u03b2-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology 96:e662\u2013e670","DOI":"10.1212\/WNL.0000000000011222"},{"key":"57_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321","journal-title":"N Engl J Med"},{"key":"57_CR137","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jid.2021.01.023","volume":"141","author":"G Vellaichamy","year":"2021","unstructured":"Vellaichamy G, Dimitrion P, Zhou L, Ozog D, Lim HW, Liao W, Hamzavi IH, Mi QS (2021) Insights from \u03b3-secretase: functional genetics of hidradenitis suppurativa. J Invest Dermatol 141:1888\u20131896","journal-title":"J Invest Dermatol"},{"key":"57_CR138","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neuron.2016.03.010","volume":"90","author":"S Veugelen","year":"2016","unstructured":"Veugelen S, Saito T, Saido TC, Ch\u00e1vez-Guti\u00e9rrez L, De Strooper B (2016) Familial Alzheimer\u2019s disease mutations in presenilin generate amyloidogenic A\u03b2 peptide seeds. Neuron 90:410\u2013416","journal-title":"Neuron"},{"key":"57_CR162","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study. Lancet Neurol 12:357\u2013367","DOI":"10.1016\/S1474-4422(13)70044-9"},{"key":"57_CR139","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archneurol.2012.540","volume":"69","author":"SL Wagner","year":"2012","unstructured":"Wagner SL, Tanzi RE, Mobley WC, Galasko D (2012) Potential use of \u03b3-secretase modulators in the treatment of Alzheimer disease. Arch Neurol 69:1255\u20131258","journal-title":"Arch Neurol"},{"key":"57_CR140","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1126\/science.1196284","volume":"330","author":"B Wang","year":"2010","unstructured":"Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T et al (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330:1065","journal-title":"Science"},{"key":"57_CR141","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nbd.2003.12.008","volume":"15","author":"J Wang","year":"2004","unstructured":"Wang J, Brunkan AL, Hecimovic S, Walker E, Goate A (2004) Conserved \u2018PAL\u2019 sequence in presenilins is essential for gamma-secretase activity, but not required for formation or stabilization of gamma-secretase complexes. Neurobiol Dis 15:654\u2013666","journal-title":"Neurobiol Dis"},{"key":"57_CR142","doi-asserted-by":"crossref","first-page":"32640","DOI":"10.1074\/jbc.M112.376541","volume":"287","author":"J Wanngren","year":"2012","unstructured":"Wanngren J, Ottervald J, Parpal S, Portelius E, Str\u00f6mberg K, Borgeg\u00e5rd T, Klintenberg R, Jur\u00e9us A, Blomqvist J, Blennow K et al (2012) Second generation \u03b3-secretase modulators exhibit different modulation of Notch \u03b2 and A\u03b2 production. J Biol Chem 287:32640\u201332650","journal-title":"J Biol Chem"},{"key":"57_CR143","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1523\/JNEUROSCI.3261-14.2014","volume":"34","author":"H Watanabe","year":"2014","unstructured":"Watanabe H, Iqbal M, Zheng J, Wines-Samuelson M, Shen J (2014) Partial loss of presenilin impairs age-dependent neuronal survival in the cerebral cortex. J Neurosci 34:15912\u201315922","journal-title":"J Neurosci"},{"key":"57_CR144","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/jcmm.17146","volume":"26","author":"TA Weber","year":"2022","unstructured":"Weber TA, Lundkvist J, Wanngren J, Kvartsberg H, Jin S, Larssen P, Wu D, Oliveira DV, Minta K, Brinkmalm G et al (2022) \u03b3-Secretase modulators show selectivity for \u03b3-secretase-mediated amyloid precursor protein intramembrane processing. J Cell Mol Med 26:880\u2013892","journal-title":"J Cell Mol Med"},{"key":"57_CR145","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T et al (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212\u2013216","journal-title":"Nature"},{"key":"57_CR146","doi-asserted-by":"crossref","first-page":"21326","DOI":"10.1074\/jbc.M112.356659","volume":"287","author":"E Winkler","year":"2012","unstructured":"Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H (2012) Generation of Alzheimer disease-associated amyloid \u03b2 42\/43 peptide by \u03b3-secretase can be inhibited directly by modulation of membrane thickness. J Biol Chem 287:21326\u201321334","journal-title":"J Biol Chem"},{"key":"57_CR147","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.embor.7400896","volume":"8","author":"MS Wolfe","year":"2007","unstructured":"Wolfe MS (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42\/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8:136\u2013140","journal-title":"EMBO Rep"},{"key":"57_CR148","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/19077","volume":"398","author":"MS Wolfe","year":"1999","unstructured":"Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513\u2013517","journal-title":"Nature"},{"key":"57_CR149","doi-asserted-by":"crossref","unstructured":"Wong E, Frost GR, Li YM (2020) \u03b3-Secretase modulatory proteins: the guiding hand behind the running scissors. Front Aging Neurosci 12:614690","DOI":"10.3389\/fnagi.2020.614690"},{"key":"57_CR150","doi-asserted-by":"crossref","first-page":"e201911104","DOI":"10.1083\/jcb.201911104","volume":"220","author":"R Wouters","year":"2021","unstructured":"Wouters R, Michiels C, Sannerud R, Kleizen B, Dillen K, Vermeire W, Ayala AE, Demedts D, Schekman R, Annaert W (2021) Assembly of \u03b3-secretase occurs through stable dimers after exit from the endoplasmic reticulum. J Cell Biol 220:e201911104","journal-title":"J Cell Biol"},{"key":"57_CR151","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuron.2015.02.010","volume":"85","author":"D Xia","year":"2015","unstructured":"Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher RJ (2015) Presenilin-1 knockin mice reveal loss-of-function mechanism for familial alzheimer\u2019s disease. Neuron 85:967\u2013981","journal-title":"Neuron"},{"key":"57_CR152","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y (2021) Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell 184:521\u2013533.e14","journal-title":"Cell"},{"key":"57_CR153","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0813-8","volume":"565","author":"G Yang","year":"2019","unstructured":"Yang G, Zhou R, Zhou Q, Guo X, Yan C, Ke M, Lei J, Shi Y (2019) Structural basis of Notch recognition by human \u03b3-secretase. Nature 565:192\u2013197","journal-title":"Nature"},{"key":"57_CR154","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcph.249","volume":"54","author":"Y Yu","year":"2014","unstructured":"Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang MK, Miyagawa T, Wong N, Ferry J (2014) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel \u03b3-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 54:528\u2013536","journal-title":"J Clin Pharmacol"},{"key":"57_CR155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nature08177","volume":"460","author":"C Zhang","year":"2009","unstructured":"Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, S\u00fcdhof TC, Shen J (2009) Presenilins are essential for regulating neurotransmitter release. Nature 460:632\u2013636","journal-title":"Nature"},{"key":"57_CR156","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/jid.2014.399","volume":"135","author":"X Zhang","year":"2015","unstructured":"Zhang X, Sisodia SS (2015) Acne inversa caused by missense mutations in NCSTN is not fully compatible with impairments in Notch signaling. J Invest Dermatol 135:618\u2013620","journal-title":"J Invest Dermatol"},{"key":"57_CR157","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1021\/acs.jmedchem.5b00774","volume":"58","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Pissarnitski DA, Josien HB, Wu WL, Xu R, Li H, Clader JW, Burnett DA, Terracina G, Hyde L et al (2015) Discovery of a novel, potent spirocyclic series of \u03b3-secretase inhibitors. J Med Chem 58:8806\u20138817","journal-title":"J Med Chem"},{"key":"57_CR158","doi-asserted-by":"crossref","first-page":"eaaw0930","DOI":"10.1126\/science.aaw0930","volume":"363","author":"R Zhou","year":"2019","unstructured":"Zhou R, Yang G, Guo X, Zhou Q, Lei J, Shi Y (2019) Recognition of the amyloid precursor protein by human g-secretase. Science 363:eaaw0930","journal-title":"Science"}],"container-title":["The EMBO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-024-00057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44318-024-00057-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-024-00057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:42:23Z","timestamp":1779237743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44318-024-00057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":160,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,15]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1038\/s44318-024-00057-w","relation":{},"ISSN":["1460-2075"],"issn-type":[{"value":"1460-2075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EK is an employee and stockholder of AbbVie. BDS is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie, and other companies. BDS is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. BDS is a member of the Advisory Editorial Board of The EMBO Journal. This has no bearing on the editorial consideration of this article for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}